Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary

<p>Abstract</p> <p>Aim</p> <p>The objective of this observational study was to assess the status of glycemic control and associated patient-reported outcomes in ambulatory Hungarian patients with type 2 diabetes mellitus (T2DM) who were prescribed either a sulfonylurea...

Full description

Bibliographic Details
Main Authors: Karve Sudeep, Phatak Hemant, Yin Don, Nagy Laszlo, Erdesz Diana, Jermendy György, Engel Samuel, Balkrishnan Rajesh
Format: Article
Language:English
Published: BMC 2008-10-01
Series:Health and Quality of Life Outcomes
Online Access:http://www.hqlo.com/content/6/1/88
id doaj-ebbedf2344f446298ae320920ed0feb4
record_format Article
spelling doaj-ebbedf2344f446298ae320920ed0feb42020-11-25T02:27:40ZengBMCHealth and Quality of Life Outcomes1477-75252008-10-01618810.1186/1477-7525-6-88Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in HungaryKarve SudeepPhatak HemantYin DonNagy LaszloErdesz DianaJermendy GyörgyEngel SamuelBalkrishnan Rajesh<p>Abstract</p> <p>Aim</p> <p>The objective of this observational study was to assess the status of glycemic control and associated patient-reported outcomes in ambulatory Hungarian patients with type 2 diabetes mellitus (T2DM) who were prescribed either a sulfonylurea (SU) or a thiazolidinedione (TZD) in addition to the prior metformin (MF) monotherapy.</p> <p>Methods</p> <p>Type 2 diabetics aged ≥ 30 years and who had added an SU or TZD to previous MF monotherapy at least 1 year prior to the visit date were identified during January 2006 to March 2007. Information on HbA1c (A1C), medication use and co-morbid conditions was extracted from the medical record up to 6 months prior to the addition of SU or TZD to MF (baseline), and a minimum of one year after the initiation of either SU or TZD. Glycemic control (A1C < 6.5%) was assessed using the last available A1C value in the medical record. Self-reported hypoglycemia, health-related quality of life (HRQoL) and treatment satisfaction were also assessed.</p> <p>Results</p> <p>A total of 414 patients (82% SU+MF and 18% TZD+MF) with a mean age of 60.5 years (SD = 9.4 years) participated in the study. About 27% of patients reported hypoglycemic episodes, with about one-third reporting episodes that resulted into interruption of activities or required medical/non-medical assistance. Three quarters of patients were not at glycemic goal and BMI was the only factor significantly associated with failure to have an A1C level < 6.5%. Patients' HRQoL was significantly associated with self-reported hypoglycemic episodes (p = 0.017), and duration of diabetes (p = 0.045).</p> <p>Conclusion</p> <p>Nearly 75% of patients were not at A1C goal of < 6.5% despite using two oral anti-hyperglycemic medications. Approximately 9% of patients reporting hypoglycemia required some kind of medical/non-medical assistance. Greater BMI at baseline was associated with an A1C level ≥ 6.5%. Finally, self- reports of hypoglycemia and duration of diabetes were associated with low HRQoL.</p> http://www.hqlo.com/content/6/1/88
collection DOAJ
language English
format Article
sources DOAJ
author Karve Sudeep
Phatak Hemant
Yin Don
Nagy Laszlo
Erdesz Diana
Jermendy György
Engel Samuel
Balkrishnan Rajesh
spellingShingle Karve Sudeep
Phatak Hemant
Yin Don
Nagy Laszlo
Erdesz Diana
Jermendy György
Engel Samuel
Balkrishnan Rajesh
Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary
Health and Quality of Life Outcomes
author_facet Karve Sudeep
Phatak Hemant
Yin Don
Nagy Laszlo
Erdesz Diana
Jermendy György
Engel Samuel
Balkrishnan Rajesh
author_sort Karve Sudeep
title Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary
title_short Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary
title_full Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary
title_fullStr Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary
title_full_unstemmed Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary
title_sort outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in hungary
publisher BMC
series Health and Quality of Life Outcomes
issn 1477-7525
publishDate 2008-10-01
description <p>Abstract</p> <p>Aim</p> <p>The objective of this observational study was to assess the status of glycemic control and associated patient-reported outcomes in ambulatory Hungarian patients with type 2 diabetes mellitus (T2DM) who were prescribed either a sulfonylurea (SU) or a thiazolidinedione (TZD) in addition to the prior metformin (MF) monotherapy.</p> <p>Methods</p> <p>Type 2 diabetics aged ≥ 30 years and who had added an SU or TZD to previous MF monotherapy at least 1 year prior to the visit date were identified during January 2006 to March 2007. Information on HbA1c (A1C), medication use and co-morbid conditions was extracted from the medical record up to 6 months prior to the addition of SU or TZD to MF (baseline), and a minimum of one year after the initiation of either SU or TZD. Glycemic control (A1C < 6.5%) was assessed using the last available A1C value in the medical record. Self-reported hypoglycemia, health-related quality of life (HRQoL) and treatment satisfaction were also assessed.</p> <p>Results</p> <p>A total of 414 patients (82% SU+MF and 18% TZD+MF) with a mean age of 60.5 years (SD = 9.4 years) participated in the study. About 27% of patients reported hypoglycemic episodes, with about one-third reporting episodes that resulted into interruption of activities or required medical/non-medical assistance. Three quarters of patients were not at glycemic goal and BMI was the only factor significantly associated with failure to have an A1C level < 6.5%. Patients' HRQoL was significantly associated with self-reported hypoglycemic episodes (p = 0.017), and duration of diabetes (p = 0.045).</p> <p>Conclusion</p> <p>Nearly 75% of patients were not at A1C goal of < 6.5% despite using two oral anti-hyperglycemic medications. Approximately 9% of patients reporting hypoglycemia required some kind of medical/non-medical assistance. Greater BMI at baseline was associated with an A1C level ≥ 6.5%. Finally, self- reports of hypoglycemia and duration of diabetes were associated with low HRQoL.</p>
url http://www.hqlo.com/content/6/1/88
work_keys_str_mv AT karvesudeep outcomesofaddingsecondhypoglycemicdrugaftermetforminmonotherapyfailureamongtype2diabetesinhungary
AT phatakhemant outcomesofaddingsecondhypoglycemicdrugaftermetforminmonotherapyfailureamongtype2diabetesinhungary
AT yindon outcomesofaddingsecondhypoglycemicdrugaftermetforminmonotherapyfailureamongtype2diabetesinhungary
AT nagylaszlo outcomesofaddingsecondhypoglycemicdrugaftermetforminmonotherapyfailureamongtype2diabetesinhungary
AT erdeszdiana outcomesofaddingsecondhypoglycemicdrugaftermetforminmonotherapyfailureamongtype2diabetesinhungary
AT jermendygyorgy outcomesofaddingsecondhypoglycemicdrugaftermetforminmonotherapyfailureamongtype2diabetesinhungary
AT engelsamuel outcomesofaddingsecondhypoglycemicdrugaftermetforminmonotherapyfailureamongtype2diabetesinhungary
AT balkrishnanrajesh outcomesofaddingsecondhypoglycemicdrugaftermetforminmonotherapyfailureamongtype2diabetesinhungary
_version_ 1724841489625776128